In Conversation with… Dr Patrick Harrington, discussing the new study on thrombosis risk in MPN patients using QRISK3 Score

The vlogcast features Dr Patrick Harrington, Consultant Haematologist, Guy’s & St Thomas’ Hospital, discussing the new study on thrombosis risk in MPN patients using QRISK3 Score.  Dr Harrington explains the research the team at Guy’s Hospital have done to see if a new way of assessing patients’ risk of thrombosis (clotting) called QRISK3, could be…

News release from Pharma& – MHRA approval of Pegasys for ET & PV patients

MHRA approves pharmaand GmbH’s Pegasys® (peginterferon alfa-2a) as a treatment for eligible patients with the myeloproliferative neoplasms (MPNs) blood cancers polycythaemia vera (PV) and essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment for adults with essential thrombocythaemia (ET) First MHRA approval of an interferon alfa as a monotherapy treatment…